连亏五年、去库存、卖资产：金种子酒还在“失血”

Core Viewpoint - Jinzhongzi Liquor (600199.SH) is expected to report a net loss of between 150 million to 190 million yuan for the year 2025, although the loss is narrowing compared to the previous year [3][14]. Financial Performance - In 2023 to Q3 2025, Jinzhongzi's revenue was 1.469 billion yuan, 925 million yuan, and 628 million yuan, with year-on-year growth rates of 23.92%, -37.04%, and -22.08% respectively [5][16]. - The net profit figures for the same periods were -19.71 million yuan, -257 million yuan, and -100 million yuan, with year-on-year changes of 89.41%, -1204.46%, and -1.72% respectively [5][16]. - The company’s revenue for the first three quarters of 2025 was significantly lower than its peers, with only 3.82% of the revenue of Gujing Gongjiu, which reported 16.42 billion yuan [6][16]. Product Performance - Revenue from low-end liquor (priced below 100 yuan) decreased by 23.79% to 330 million yuan, while mid-range liquor (100-500 yuan) fell by 23.83% to 131 million yuan. Only high-end liquor (above 500 yuan) saw a slight increase of 7.33% to 51.27 million yuan [6][18]. - The total revenue from all product categories in Q3 2025 was 512.23 million yuan [19]. Market and Channel Dynamics - The number of distributors for Jinzhongzi decreased to 629 by Q3 2025, down by 13 from the beginning of the year, indicating a contraction in market channels [8][19]. - Revenue from the domestic market fell by 18.16% to 419 million yuan, while revenue from the external market dropped by 33.78% to 93.52 million yuan [20]. Inventory and Cash Flow Issues - As of Q3 2025, Jinzhongzi's inventory stood at 1.531 billion yuan, accounting for 76.13% of its current assets, indicating a high level of liquidity tied up in inventory [8][20]. - The cash flow from operating activities was -118 million yuan for the first three quarters of 2025, marking a continued negative trend since 2016, except for a brief positive cash flow in 2023 [10][21]. Asset Disposal - In November 2025, the company sold 92% of its subsidiary, Jintaiyang Pharmaceutical, for 126 million yuan, a 10% discount from the initial listing price [10][22]. - This asset sale is viewed as a temporary measure, and the company needs to focus on product upgrades, channel expansion, and market demand to address deeper operational issues [10][22].